Literature DB >> 28753760

Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer.

Stephen B Williams1, Jinhai Huo2, Karim Chamie3, Jim C Hu4, Sharon H Giordano2, Karen E Hoffman5, Colin P N Dinney6, Ashish M Kamat6, Ya-Chen Tina Shih2.   

Abstract

BACKGROUND: Radical cystectomy is the standard surgical treatment for muscle-invasive bladder cancer (MIBC).
OBJECTIVE: We sought to identify population-based factors predicting the use of radical cystectomy. DESIGN, SETTING, AND PATIENTS: Analysis of Surveillance, Epidemiology, and End Results (SEER)-Medicare data for 3922 patients aged ≥66 yr diagnosed with clinical stage T2 MIBC from January 1, 2002 to December 31, 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We used univariate and multivariable regression analyses to identify factors predicting the use of radical cystectomy. Cox proportional hazards models were used to analyze survival outcomes. RESULTS AND LIMITATIONS: A total of 740 (18.9%) patients with MIBC underwent radical cystectomy. Older age at diagnosis (>80 vs 65-69 yr, odds ratio [OR] 0.15, 95% confidence interval [CI] 0.11-0.19; p<0.001) and higher comorbidity (Charlson comorbidity index 3+ vs 0, OR 0.41, 95% CI 0.29-0.57; p<0.001) were associated with lower use of radical cystectomy. Moreover, non-Hispanic black patients were less likely than white patients to undergo radical cystectomy (OR 0.62, 95% CI 0.40-0.96; p=0.032) and pelvic lymph node dissection (OR 0.65, 95% CI 0.42-1.02; p=0.058). Overall survival was better for patients who underwent radical cystectomy alone (hazard ratio [HR] 0.70, 95% CI 0.56-0.88; p=0.002) and with lymph node dissection (HR 0.45, 95% CI 0.40-0.51; p<0.001). Limitations include the limited ability of retrospective analysis to demonstrate causality.
CONCLUSIONS: There is significant underutilization of radical cystectomy among patients diagnosed with MIBC, especially among older patients with significant comorbidities and non-Hispanic black patients. PATIENT
SUMMARY: Despite guideline recommendations, there is significant underutilization of radical cystectomy among patients diagnosed with bladder cancer, especially for non-Hispanic black patients and older patients with significant comorbidities.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Disparities; Radical cystectomy; Utilization

Mesh:

Year:  2016        PMID: 28753760     DOI: 10.1016/j.euf.2016.04.008

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN: 2405-4569


  18 in total

1.  Racial and Socioeconomic Disparities in Bladder Cancer Survival: Analysis of the California Cancer Registry.

Authors:  John M Sung; Jeremy W Martin; Francis A Jefferson; Daniel A Sidhom; Keyhan Piranviseh; Melissa Huang; Nobel Nguyen; Jenny Chang; Argyrios Ziogas; Hoda Anton-Culver; Ramy F Youssef
Journal:  Clin Genitourin Cancer       Date:  2019-05-31       Impact factor: 2.872

2.  Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.

Authors:  Stephen B Williams; Yong Shan; Usama Jazzar; Hemalkumar B Mehta; Jacques G Baillargeon; Jinhai Huo; Anthony J Senagore; Eduardo Orihuela; Douglas S Tyler; Todd A Swanson; Ashish M Kamat
Journal:  JAMA Surg       Date:  2018-10-01       Impact factor: 14.766

3.  Studying the impact of comorbidity on post radical cystectomy survival: have we come a full circle?

Authors:  Subodh K Regmi; Badrinath R Konety
Journal:  Transl Androl Urol       Date:  2019-07

4.  Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-making.

Authors:  Stephen B Williams; Jinhai Huo; Yiyi Chu; Jacques G Baillargeon; Timothy Daskivich; Yong-Fang Kuo; Christopher D Kosarek; Simon P Kim; Eduardo Orihuela; Douglas S Tyler; Stephen J Freedland; Ashish M Kamat
Journal:  Urology       Date:  2017-08-25       Impact factor: 2.649

5.  Hospital length of stay following radical cystectomy for muscle-invasive bladder cancer: Development and validation of a population-based prediction model.

Authors:  Mohamed D Ray-Zack; Yong Shan; Hemalkumar B Mehta; Xiaoying Yu; Ashish M Kamat; Stephen B Williams
Journal:  Urol Oncol       Date:  2018-11-13       Impact factor: 3.498

Review 6.  Defining cisplatin eligibility in patients with muscle-invasive bladder cancer.

Authors:  Di Maria Jiang; Shilpa Gupta; Abhijat Kitchlu; Alejandro Meraz-Munoz; Scott A North; Nimira S Alimohamed; Normand Blais; Srikala S Sridhar
Journal:  Nat Rev Urol       Date:  2021-01-11       Impact factor: 14.432

7.  Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer.

Authors:  Stephen B Williams; Jinhai Huo; Christopher D Kosarek; Karim Chamie; Selwyn O Rogers; Michele A Williams; Sharon H Giordano; Simon P Kim; Ashish M Kamat
Journal:  Cancer Causes Control       Date:  2017-05-05       Impact factor: 2.506

8.  Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer.

Authors:  Stephen B Williams; Yong Shan; Mohamed D Ray-Zack; Hogan K Hudgins; Usama Jazzar; Douglas S Tyler; Stephen J Freedland; Todd A Swanson; Jacques G Baillargeon; Jim C Hu; Sapna Kaul; Ashish M Kamat; John L Gore; Hemalkumar B Mehta
Journal:  JAMA Surg       Date:  2019-08-21       Impact factor: 14.766

9.  Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.

Authors:  Stephen B Williams; Ashish M Kamat; Karim Chamie; Michael Froehner; Manfred P Wirth; Peter N Wiklund; Peter C Black; Gary D Steinberg; Stephen A Boorjian; Sia Daneshmand; Peter J Goebell; Kamal S Pohar; Shahrokh F Shariat; George N Thalmann
Journal:  Eur Urol Oncol       Date:  2018-06-06

10.  Commentary: underutilization of curative-intent therapy for patients with muscle-invasive bladder cancer in Sweden mimics the United States.

Authors:  Timothy N Clinton; Michal Wiseman; Aleksandra Walasek; Eugene Pietzak
Journal:  Transl Androl Urol       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.